New Zealand markets closed

ICPT Jan 2024 12.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
6.300.00 (0.00%)
At close: 03:57PM EDT
Full screen
Previous close6.30
Open6.30
Bid5.60
Ask7.70
Strike12.50
Expiry date2024-01-19
Day's range6.30 - 6.30
Contract rangeN/A
Volume2
Open interest6
  • GlobeNewswire

    Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

    Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced a summary of t

  • GlobeNewswire

    Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

    Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to natural history data from the Global PBC and UK-PBC patient registries MORRISTOWN, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral li

  • Zacks

    Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

    Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.